若生智能
Drug Database
SA

saxagliptin (Bessin)

✓ Approved

Sino Biopharmaceutical Co., Ltd · DPP4 · 小分子

什么是 saxagliptin？

saxagliptin 是一种小分子，由Sino Biopharmaceutical Co., Ltd研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Bessin
公司Sino Biopharmaceutical Co., Ltd
药物类别小分子
分子靶点DPP4
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Sino Biopharmaceutical Co., Ltd

作用机制

分子靶点

saxagliptin 作用于 1 个分子靶点：

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

saxagliptin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedHealth science reports2026-08-05

The Role of Research, Quality Improvement, and Training in Achieving Medicines Security in Nigeria: A Cross-Sectional Exploration of Stakeholders' Perspectives.

Adigwe Obi Peter OP, Onavbavba Godspower G, Alabi Toluwalope Folashade TF, Uzuh Nwakaego Rosemary NR

Equitable access to medicines remains a challenge in Nigeria with issues such as sub-optimal national pharmaceutical production capacities and the need to improve relevant quality standards. Thus, in order to identify context-specific solutions to this challenge, this study aimed to assess the perspectives of stakeholders in the healthcare value chain on the role of quality improvement and capacity-building strategies relevant to expediting medicines security in Nigeria. A national cross-sectional survey was conducted in Nigeria using a multistage sampling technique. A pretested questionnaire was administered to relevant stakeholders in the health sector. Descriptive and inferential statistical analyses were undertaken using Statistical Package for Social Sciences (SPSS) software version 25. A total of 416 questionnaires were retrieved. Just over a third of the study participants (37.9%) surveyed were actively employed in the pharmaceutical manufacturing sector. Nearly all the participants (94.8%) believed regulatory authorities should ensure the stringent implementation of Good Manufacturing Practices to sustain consistency in the quality of medicines. Similarly, over three-quarters of the study cohort (86.1%) indicated that the pharmaceutical sector, as well as relevant agencies in the industry, should be prioritised by the government, as this was critical in achieving medicines security. Also, a strong majority of the participants indicated that attaining the World Health Organization pre-qualification status was necessary to ensure access to high-quality medicines. There was a significant association between the participants' sociodemographic characteristics and key study variables. A higher proportion of the respondents with more than 5 years of experience agreed that investment in research and development was important to improve the quality of medicines, and this was statistically significant (p = 0.009). This cross-sectional study highlights strategic areas based on stakeholders' perceptions where interventions and reforms can be channelled to support efforts towards expediting the achievement of medicines security in Nigeria.

PMID 42553489
阅读全文 →
PubMedJournal of toxicology and environmental health. Part A2026-08-05

Effects of early-life exposure to Venlafaxine in Caenorhabditis elegans.

Alves Carla C, Tamagno Wagner Antonio WA, Pompermaier Aline A, Barcellos Leonardo José Gil LJG

Improper disposal of contaminants in wastewater may adversely impact organisms across multiple biological levels, including exposure to pharmaceutical and personal care products (PPCPs). Venlafaxine (VFX), a frequently prescribed antidepressant, is a drug of concern due to its potential environmental and neurotoxic effects. The concentrations of VFX used in this study were selected to span a range relevant to both acute toxicological testing and higher-end environmental contamination scenarios. Higher concentrations may occur in wastewater effluent, hospital discharge, or pharmaceutical manufacturing waste streams. This study investigated the effects of early-in-life (pre-and neonatal) VFX exposure on Caenorhabditis elegans at concentrations of 0, 9.37, 18.75, 28.12, or 37.5 mg/L. Neurobehavioral and cholinergic endpoints were assessed at the L4 stage to assess long-term neurotoxicity. Data demonstrated that worms exposed to the highest concentration exhibited increased locomotor activity, while pharyngeal pumping was elevated at both 9.37 and 37.5 mg/L. Acetylcholinesterase (AChE) activity was decreased at 9.37 and 28.12 mg/L. Early-life VFX exposure also altered social feeding behavior, with worms showing a preference for bacterial lawn border (18.75 and 37.5 mg/L) and enhanced group feeding (28.12 and 37.5 mg/L). These results indicate that neonatal VFX exposure induces behavioral and neurochemical changes in C. elegans, associated with disruption of the cholinergic system.

PMID 42553005
阅读全文 →
PubMedElectrophoresis2026-08-05

High-Throughput Multi-Capillary Electrophoresis.

Drewes Jana J, Meyer Sarah S, Roberts Isobel I, Fanny Cleo C et al.

The potential of multi-capillary electrophoresis (CE) for high-throughput analysis of legacy CE applications was investigated by optimisation of the separation of six pharmaceutical compounds on a single-capillary instrument, followed by transference of the method to an eight-capillary BioPhase 8800 system from SCIEX. Multi-CE had superior performance, allowing construction of calibration curves in a single run, and a five-fold reduction of run time per sample, improved linearity, accuracy and limits of detection. Method transfer from the single-capillary system required minor instrumental parameter adjustments using the same background electrolyte. The potential of multi-CE was shown via quantification of caffeine in a variety of energy drinks, demonstrating broad applicability where high-throughput and rapid analyses are desirable.

PMID 42552802
阅读全文 →
PubMedApplied and environmental microbiology2026-08-05

Characterization of successive ortho-methyl oxidation of the priority pollutant 2,4-xylenol by a Rieske oxygenase system in Pseudomonas putida NCIMB 9866.

Meng Haiqin H, Pan Shun S, Chai Zening Z, Zhou Lixiang L et al.

The catabolism of the priority environmental pollutant 2,4-xylenol requires bacteria to oxidize its ortho-methyl group. Its exact biochemical mechanism is uncharacterized until now. In this study, we resolve key metabolic bottlenecks in Pseudomonas putida NCIMB 9866. We demonstrate that functionally redundant Rieske oxygenase systems ensure the robust ortho-methyl oxidation of 2,4-xylenol. On the para-methyl oxidation branch, PchA2 acts as the main aldehyde dehydrogenase. It shows significantly higher catalytic efficiency than the previously reported PchA. Additionally, we characterized PmmA1B1, a newly identified three-component Rieske oxygenase system responsible for ortho-methyl oxidation, which is supported by two redundant isoenzymes (PmmA2B2 and PmmA3B3), by recruiting the shared endogenous ferredoxin Orf05169. The PmmA1B1-Orf05169 system catalyzes the successive oxidation of the ortho-methyl group of 4-hydroxy-3-methylbenzoate to a carboxyl group, yielding the high-value pharmaceutical precursor 4-hydroxyisophthalate. Structural and kinetic data revealed that the active site architecture of PmmA1 enables efficient successive oxidation, distinguishing it from isoenzymes PmmA2B2 and PmmA3B3 that, when coupled with Orf05169, catalyze only incomplete oxidation. Overall, these results complete the 2,4-xylenol catabolic pathway by defining the enzymes required for both para- and ortho-methyl oxidation. They also reveal functional redundancy as an adaptive feature of microbial aromatic degradation and establish Rieske oxygenases as biocatalysts for converting methylated aromatic pollutants into value-added chemicals.IMPORTANCEMethylated aromatics like 2,4-xylenol pose ongoing environmental risks and are primary targets for bioremediation. We know how bacteria break down many simple aromatics, but the precise ways that enzymes bypass the steric and electronic hurdles of hindered methyl groups remain unclear. In this study, we characterized a novel three-component Rieske oxygenase, PmmA1B1-Orf05169, capable of a rare successive oxidation that turns an ortho-methyl group directly into a carboxyl group. We also found parallel, redundant oxygenase pathways that protect the bacterium's ability to degrade 2,4-xylenol during environmental stress or genetic loss. This discovery not only completes the metabolic map of 2,4-xylenol but also provides a robust biocatalytic tool for the green synthesis of 4-hydroxyisophthalate, a high-value pharmaceutical precursor.

PMID 42554493
阅读全文 →
PubMedBiomedical chromatography : BMC2026-08-05

Stress-Induced Degradation Profiling of Satranidazole Using Stability-Indicating RP-HPLC Method and LC-MS Characterization.

Saraf Bhairavi B, Mehta Preeti P, Somani Rahul R

A stability-indicating reverse-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for quantitative estimation of satranidazole in bulk drug and tablet dosage form, followed by LC-MS characterization of stress-induced degradation products. Chromatographic separation was achieved on a HiQ Sil C18 column (250 × 4.6 mm, 5 μm) using methanol:0.1% formic acid in water (60:40, v/v) as mobile phase at a flow rate of 1.0 mL/min with UV detection at 317 nm. The method exhibited satisfactory linearity over 5-30 μg/mL with a correlation coefficient of 0.999. Stress-induced degradation studies performed under acidic, alkaline, oxidative, thermal, and photolytic conditions demonstrated significant degradation under alkaline and photolytic stress. The developed method successfully resolved satranidazole from its degradation products. LC-MS analysis enabled tentative characterization of major degradants and facilitated the proposal of probable degradation pathways. The developed method is suitable for routine stability assessment and pharmaceutical quality control of satranidazole formulations.

PMID 42552616
阅读全文 →
PubMedJournal of the peripheral nervous system : JPNS2026-08-05

Clinical Development of Therapies for Charcot-Marie-Tooth Disease: Recommendations for Trial Design, Endpoints, and Regulatory Pathways.

Abrams Charles K CK, Bruhn Sue S, Burns Joshua J, Fleming Rebekah R et al.

Charcot-Marie-Tooth disease (CMT) encompasses a heterogeneous group of inherited peripheral neuropathies. Despite being the most common genetic neurological condition, individual CMT subtypes are rare, presenting unique challenges for therapeutic development. The Together Patients Industry Clinicians versus CMT (ToPIC: CMT) Advocacy Group was formed with a diverse group of patient advocacy groups, clinician-scientists who treat patients with CMT, and pharmaceutical industry representatives to develop a common guidance on development of new treatments for CMT with clear expectations for meaningful patient outcomes and objective assessments of improvement. The ToPIC: CMT Group developed recommendations for clinical development of drugs and biological products for treating CMT, addressing trial design considerations for this rare progressive disease. Key challenges in CMT include small patient populations, variable disease progression, and the need for sensitive outcome measures. Recommendations emphasize flexible trial designs including adaptive designs, external controls, and single-participant designs when scientifically justified. Where possible, broad inclusion criteria based on clinical phenotype rather than genetic subtype alone are recommended. Disease-specific, validated outcome measures should assess function across ages and disease stages. Biomarkers reflecting peripheral nervous system health may serve as surrogate endpoints to support accelerated approval pathways. Patient and care partner perspectives are essential throughout development, particularly regarding treatment goals, risk tolerance, and meaningful endpoints. Successful therapeutic development for CMT and related neuropathies requires innovative approaches that balance rigorous scientific standards with the realities of rare disease research. Regulatory flexibility, informed by patient input and natural history data, can facilitate efficient development while maintaining assurance of safety and effectiveness.

PMID 42552689
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多saxagliptin